Skip to main content

Company News

October 23, 2024

Global Response to the 2024 Mpox Outbreak: Need for Enhanced Diagnostics and Equitable Resource Distribution

Fast, effective diagnostics are crucial in the identification of individuals infected with monkeypox (MPXV); a potentially fatal virus previously known as monkeypox. The outbreak was declared a public health emergency of international concern by the World Health Organization (WHO) in August 2024, just two years after a similar occurrence in 2022. Many top health officials have called for a coordinated international response to curb the spread and save lives. Drawing on this experience, University of Alabama at Birmingham Professor and epidemiologist David O. Freedman, contributes insights into managing outbreaks in a post-pandemic world.
Discover More

  • September 18, 2024

    Global In Vitro Diagnostics Leader bioMérieux Celebrates the Opening of the Molecular & Genomic Innovation Center at the Navy Yard in Philadelphia

    bioMérieux, a world leader in in vitro diagnostics, celebrates the opening of the company’s Molecular & Genomic Innovation Center. The new 32,000 sq. ft. facility is home to the xPRO™ Program, which has rapidly changed the landscape of food safety diagnostic capabilities by partnering directly with industry leaders to address unmet needs to streamline operational efficiencies and further public health.

    Read more

  • September 02, 2024

    France: the bioMérieux bioindustrial and R&D site of La Balme is diversifying

    Two strategic infrastructures were inaugurated this year on the bioMérieux site of La Balme-les-Grottes (Isère, France): a plastic injection unit in June and a new-generation R&D building in September. The global specialist in in vitro diagnostics is continuing its investments in France, aiming to develop new solutions for public health worldwide.
    Read more

  • August 21, 2024

    Extremely promising clinical trial results for the high-sensitivity Point-of-Care (POC) cardiac troponin I test of our partner SpinChip Diagnostics

    SpinChip Diagnostics, in which bioMérieux has held an approximate 20% stake since March 2024, has just published results showing the very good performance of its high-sensitivity Point-of-Care (POC) cardiac troponin I (hs-cTnI) assay. This innovative assay, the first of its kind, could significantly improve the diagnosis of acute myocardial infarction.
    Read more

  • July 26, 2024

    Paris 2024: National teams choose bioMérieux’s BIOFIRE® PCR solutions to test athletes

    During this summer's Olympic and Paralympic Games in Paris, several committees and national teams, including the Dutch delegation, will be using the BIOFIRE® range of PCR test solutions developed by bioMérieux to detect respiratory and gastrointestinal infections in their athletes.
    Read more

Follow us on Socials for more news!